title: Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS).
abstract: BACKGROUND
  Prospective longitudinal examinations of anthracycline-induced cardiomyopathy in a homogeneous cohort are rare in pediatric oncology. We herein report the results of observations on the frequency of cardiomyopathy in doxorubicin-treated sarcoma patients in Germany, Austria, and Switzerland.
  
  
  METHODS
  The Late Effects Surveillance System (LESS) prospectively collects longitudinal data on late sequelae of antineoplastic therapy in Ewing-, soft tissue-, and osteosarcoma patients treated within the therapy trial protocols of the German Society of Pediatric Oncology and Hematology. Two hundred sixty-five relapse-free patients who had received doxorubicin for the treatment within the EICESS-92/EURO-E.W.I.N.G.-99, COSS-96, and CWS-96 therapy trials were serially examined by echocardiography. The analyzed population consisted of 142 males and 123 females. Their mean age at the end of therapy was 13 +/- 5 years. The mean follow-up time was 34 +/- 12 months. The mean cumulative doxorubicin dose was 290 +/- 91 mg/m(2).
  
  
  RESULTS
  In this cohort, the total cumulative incidence of doxorubicin-induced cardiomyopathy was 7.5%. Four patients (1.5%) suffered from a symptomatic cardiomyopathy and 16 (6%) from a subclinical cardiomyopathy. Cardiomyopathy manifested in 11 cases already under antineoplastic therapy and in the remaining nine cases at a median of 26 days (range: 17-174 days) after stopping antineoplastic therapy. Univariate and multivariable analysis did not confirm any of the known risk factors for developing anthracycline-induced cardiomyopathy in our patient group within the described time interval.
  
  
  CONCLUSIONS
  After a mean follow-up of 34 +/- 12 months, cumulative incidence of doxorubicin-induced cardiomyopathy in our pediatric sarcoma patients was at the lower end of that reported by other groups.
authors.affiliation: Department of Pediatric Oncology, LESS Centre, University Hospital for Children and Adolescents, Erlangen, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Paulides
authors.forename: A
authors.initials: A
authors.lastname: Kremers
authors.forename: W
authors.initials: W
authors.lastname: Stöhr
authors.forename: S
authors.initials: S
authors.lastname: Bielack
authors.forename: H
authors.initials: H
authors.lastname: Jürgens
authors.forename: J
authors.initials: J
authors.lastname: Treuner
authors.forename: J D
authors.initials: JD
authors.lastname: Beck
authors.forename: T
authors.initials: T
authors.lastname: Langer
mesh_terms: D000293:Adolescent; D000328:Adult; D001317:Austria / Q000453:epidemiology; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000188:drug therapy / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D015897:Comorbidity; D004317:Doxorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D006801:Humans; D007223:Infant; D008137:Longitudinal Studies; D008297:Male; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D012509:Sarcoma / Q000188:drug therapy* / Q000453:epidemiology; D013557:Switzerland / Q000453:epidemiology; D013995:Time
chemical_list: D004317:Doxorubicin